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Histology of autoimmune hepatitis (AIH), chronic active hepatitis, is characterized by 
portal inflammation with interface hepatitis. Although the basic histology of AIH is 
similar to that of virus-related chronic hepatitis, hepatitic changes are usually prominent 
in AIH compared with chronic viral hepatitis. Clinicopathological diagnosis of AIH 
requires exclusion of other causes of liver disease, including hepatitis virus, alcohol, 
drugs, metabolic disorders, and other autoimmune diseases. At present, some criteria 
systems considering clinicopathological findings are proposed to categorize patients as 
having either “definite” or “probably/atypical” AIH. Among the pathological items of a 
simplified AIH scoring system of the International AIH Group, in addition to evident 
chronic hepatitis with interface hepatitis and hepatic rosette formation, emperipolesis, 
indicating the close immunological interaction of lymphocytes and hepatocytes, is noted 
but is sometimes difficult to evaluate. In addition to classical AIH, showing chronic 
active hepatitis, some AIH patients show a clinically acute hepatitis-like clinical course. 
These patients have mostly acute exacerbation from chronic active AIH, but acute-onset 
AIH cases, which histologically exhibit diffuse lobular hepatitis and/or confluent 
necrosis including perivenular zonal necrosis (zone 3 necrosis, centrizonal necrosis), are 
also encountered. 
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4.1 Introduction 
Chronic hepatitis is defined as an inflammatory disease of the liver that lasts for more 
than six months. Histologically, chronic active hepatitis accompanies interface hepatitis 
(formerly termed piecemeal necrosis). As an etiology, viral hepatitis (hepatitis B virus, 
hepatitis C virus, etc.), metabolic disease [nonalcoholic fatty liver disease (NAFLD), 
Wilson’s disease, etc.], toxic agents and drugs (alcoholic liver disease, aminodarone, 
etc.), autoimmune disease [autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), 
primary sclerosing cholangitis (PSC), and sarcoidosis] have been described. In 
particular, AIH preferably affects middle-aged women and is characterized by chronic 
active hepatitis related to autoimmune-mediated and continuous hepatocellular damage. 
Usually, it can be readily distinguished from the other two major autoimmune liver 
diseases, PBC and PSC, but overlap syndromes exist. However, AIH lacks 
pathognomonic features and histological manifestations are observed in acute and 
chronic liver diseases of diverse causes. 
 
4.2 Basic histology of AIH 
 Basic histology of AIH includes chronic active hepatitis characterized by portal 
inflammation with interface hepatitis; lymphoplasmacytic infiltration and follicle-like 
aggregation of lymphocytes in portal tracts (Figs 1 and 2), fibrous enlargement of portal 
tracts with fibrous septa formation, hepatocellular damage and necrosis/apoptosis 
around portal tracts with the destruction of limiting plates (interface hepatitis) (Fig. 2), 
parenchymal necroinflammatory changes including focal necrosis (lobular hepatitis) 
(Fig. 3), and sinusoidal lymphocytic infiltration. In particular, interface hepatitis is a 
pathogenic hallmark of chronic active AIH and is prominent during disease flares. 
These histologies are similar to those observed in chronic active hepatitis caused by 
viral infection and are not specific for AIH. Interface hepatitis may occur even in biliary 
diseases such as PBC. However, compared with those observed in chronic viral hepatitis, 
the hepatitic changes that are prominent in typical AIH include the following: 
infiltration and accumulation of marked plasma cells in portal tracts, confluent necrosis 
(bridging and zonal necrosis) (Fig. 4), ballooning degeneration of hepatocytes (Fig.5) 
and many acidophilic bodies (apoptosis of hepatocytes) (Fig. 6), rosette formation of 
hepatocytes (Fig. 7), and pigmented macrophages (pigment-laden or ceroid-laden 
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macrophages) (Fig. 8). As for the predominant plasma cell infiltration, this feature does 
not occur in all patients with AIH [1]. Its presence supports the diagnosis of AIH 
because it is a finding that is more common in AIH (66%) than in chronic hepatitis B 
(40%) or chronic hepatitis C (21%). In severe cases and acute exacerbation of AIH, 
giant cell formation of hepatocytes (giant syncytial multinucleated hepatocytes) (Fig. 9), 
broad hepatocellular collapse (Fig. 10), and multiple confluent necrosis consisting zonal 
and bridging necrosis are observed. Cases of fulminant hepatitis, histologically showing 
submassive and massive necrosis, are also present. In addition to severe lobular necrosis 
including massive hepatocyte necrosis and drop out, regeneration of hepatocytes may be 
present and mimic parenchymal nodules of established cirrhosis in the recovery phase 
of fulminant AIH. 
 
4.3 Pathogenesis of AIH from the aspect of pathogenic and regulatory helper T cells 
 Several studies, including animal model studies, have been reported for the 
pathogenesis of AIH. It is postulated that an environmental agent, either a drug, virus, or 
other agent, appears to trigger a T cell-mediated cascade directed against hepatocellular 
antigens in genetically predisposed individuals to cause AIH. Immunohistochemically 
CD8+ T cells are a dominant subset of lymphocytes observed within the area of 
interface hepatitis and CD4+ T cells predominate within the portal tracts [2]. CD4+ 
helper T cells are essential regulators of immune responses and inflammatory diseases. 
Immunoreactivity to intra- and extracellular antigens is regulated mainly by two 
different types of memory CD4+helper T cells, i.e., Th1 and Th2 cells, which are 
principally distinguished by their production of different cytokines and their ability to 
induce either cellular (Th1) or humoral (Th2) immune reactions. The advancement of 
the understanding of polarized Th1 and Th2 cells in human diseases suggests that the 
balance between these two subsets is altered in autoimmune disorders; organ-specific 
autoimmune diseases, including AIH, are mainly mediated by Th1 cells, whereas the 
Th2 subset predominates in systemic autoimmune disorders [3-5]. 
Immunohistochemically, Th1 and Th2 cells are easily distinguishable by the 
transcription factors T-box expressed in T cells (T-bet) and GATA-binding protein-3 
(GATA-3), respectively, in addition to Th1-type cytokines (IL-2 and IFN-γ) and 
Th2-type cytokines (IL4, IL10, and IL13). In fact, many T-bet-positive lymphocytes 
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infiltrate the portal tracts and parenchyma (Fig. 11), whereas GATA-3-positive cells are 
scarce. Of late, a third pathogenic type, Th17 cells, and their association with the 
chronic inflammation present in autoimmune diseases via the production of the 
proinflammatory cytokines IL-17, IL-22, and TNF-α, have been noted [6-9]. Th17 cells 
are elevated in the circulation and liver of patients with AIH and contribute to 
autoimmunity against hepatocytes by inducing the secretion of IL-6 by these cells [10]. 
Both natural Tregs (nTregs, Foxp3+CD25+Tregs), which originate in CD4+ T cells in the 
thymus, and induced Tregs (iTregs, Foxp3+Tregs), which develop in the periphery, can 
play a role of dominant immunosuppression on effector T cells and antigen-presenting 
cells. Patients with AIH have a reduced number and function of 
CD4+CD25+FOXP3+Tregs [11,12]. However, a controversial study has reported that the 
frequency and function of circulating Tregs is not impaired in AIH (Fig. 11) [13]. 
 
4.4 Pathological diagnosis—histological components of the AIH diagnostic scoring 
system 
 The clinicopathological diagnosis of AIH requires the exclusion of other causes of 
liver disease, including viral hepatitis, alcohol and drug abuse, metabolic disorders 
(NAFLD and NASH), and other autoimmune diseases. In particular, the pathological 
differentiation of AIH from chronic viral hepatitis and the presence of AIH 
superimposed on HCV-infected patients is difficult or impossible in most cases. 
Pathologically, the histological difference between AIH and chronic viral hepatitis 
depends on the relative evaluation of several findings regarding chronic active hepatitis. 
Therefore, some systems of criteria that take into consideration clinicopathological 
findings have been proposed to categorize patients as having either “definite” or 
“probably/atypical” AIH. The criteria of the Intractable Hepatobiliary Disease Study 
Group in Japan (2013) [14] includes the following: 1) exclusion of other causes of liver 
disease, 2) positivity for the antinuclear antibody (ANA) and/or antismooth muscle 
antibody, 3) increased IgG level (>1.10 times the upper normal limit), 4) interface 
hepatitis and plasma cell infiltration in liver tissues, and 5) marked efficacy of steroid 
therapy. Typical AIH is defined as the presence of 1) and another three items among 
2)–5), and the atypical cases are defined as those exhibiting 1) and another one or two 
item(s) among 2)–5). In addition to these Japanese AIH criteria, the AIH scoring system 
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of the International AIH Group (IAIHG) is useful. At present, modified criteria (1999) 
[15] and simplified criteria (2008) [16] are used. The former consist of many items and 
are complex; however, it is possible to adequately distinguish AIH from other liver 
diseases, particularly primary biliary diseases, such as PBC and PSC, and chronic viral 
hepatitis. Pathological items consist of interface hepatitis (+3), predominantly 
lymphoplasmacytic infiltrate (+1), rosette of liver cells (+1), none of the above (−5), 
biliary changes (−3), and other changes (−3), which make up score 5 in full score 29. 
The most important point is that biliary changes and other changes suggestive of other 
hepatobiliary diseases, including PBC and PSC, and a different etiology, respectively, 
provide negative points toward the accurate identification of AIH alone. “Biliary 
changes” refers to bile duct changes that are typical of PBC or PSC (i.e., granulomatous 
cholangitis or severe concentric periductal fibrosis with ductopenia established in an 
adequate biopsy specimen) and/or a substantial periportal ductular reaction with 
copper/copper-associated protein accumulation (Fig. 12). The deposition of copper 
reflects chronic cholestasis [17,18], and orcein staining is very useful to detect the 
deposition of copper-binding proteins. This deposition in the early stage of chronic liver 
diseases suggests cholestatic liver diseases, such as PBC, PSC, and Wilson’s disease; 
however, in advanced liver diseases, including cirrhosis, this deposition in hepatocytes 
is usually observed, regardless of etiology. Pathologists, therefore, have to evaluate 
orcein staining results with caution to avoid over diagnosing biliary diseases. In contrast, 
the simplified criteria [16] have been proposed for the rapid diagnosis and treatment for 
AIH and are useful to nonspecialized and specialized hepatologists. Regarding the 
pathological items in this criteria, three categories are defined for grading histology and 
give out a score of 0–2 in full score 8; atypical histology (0 points), histology 
compatible with AIH (1 point), and typical histology (2 points). In addition to evident 
hepatitis as a necessary condition, interface hepatitis, lymphocytic/lymphoplasmacytic 
infiltrates in portal tracts and extends into the lobule, emperipolesis, and hepatic rosette 
formation are regarded as typical for the diagnosis of AIH. To be considered typical, 
each of the three features of typical AIH histology has to be present. Compatible 
features are a picture of chronic hepatitis with lymphocytic infiltration without all the 
features that are considered typical. Histology is considered atypical when signs of 
another diagnosis, such as steatohepatitis, are present. These findings reflect chronic 
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hepatitis with severe activities; however, it is impossible to establish a definite diagnosis 
of AIH on the basis of these findings because they are not specific to AIH. Because 
atypical AIH cases, such as acute onset and excavation AIH, are probably ruled out as 
being non-AIH when using the simplified criteria, the modified criteria (1999) should 
be applied in these cases. Moreover, steatohepatitis is considered as a disease that is 
difficult to differentiate from AIH based on these criteria, and ANA is detected in 
approximately one third of cases of NASH and NAFLD [19,20], although pathological 
differentiation is relatively easy on liver biopsy. 
 Among the histological findings of the simplified IAIHG criteria, emperipolesis is 
unfamiliar in the hepatology field but is pathologically well known as a characteristic of 
the Rosai–Dorfman disease (sinus histiocytosis with massive lymphadenopathy). 
Emperipolesis is an active penetration by one cell into and through a larger cell and is 
immunologically the strongest pattern of cell-to-cell contact (Fig. 13). Although 
lymphocytes are frequently found in close contact with hepatocytes and bile ducts in 
various hepatobiliary diseases, the presence of emperipolesis indicates the close 
immunological interaction of immune competent cells (lymphocytes) and target cells 
(hepatocytes) in AIH. In addition to rosette formation of hepatocytes, this emperipolesis 
is frequently observed in hepatocytes around the interface hepatitis of AIH with severe 
hepatitic changes (Fig. 14). At present, emperipolesis is noted as a pathological finding 
and is included in the simplified criteria of AIH. However, this finding was primarily 
reported in the field of hepatology as a histological finding of HBV-related chronic viral 
hepatitis [21] and is found in other hepatitic diseases with chronic active hepatitis and 
AIH. In practice, in the establishment of a pathological diagnosis using HE staining, it is 
always difficult to distinguish emperipolesis from apoptotic body-laden macrophages 
and to differentiate whether lymphocytes are located inside or outside of hepatocytes. 
Because the presence or absence of emperipolesis greatly affects the score of simplified 
AIH criteria (1 in a full score of 8) [16], the survey of emperipolesis is a heavy burden 
for pathologists. 
Compared with the histology of chronic viral hepatitis, several of the findings 
that indicate the possibility of AIH described above are observed in AIH, but all these 
findings are not observed in needle liver specimens. However, the presence of highly 
active hepatitis is necessary for the pathological diagnosis of pretreated AIH cases, and 
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chronic hepatitis with broad hepatocellular necrosis should be suspected as AIH. Bile 
duct damages are thought to be a histological characteristic of PBC and PSC. However, 
bile duct damage is often observed in AIH with severe portal inflammation (Fig. 15). 
This bile duct damage is called hepatitic bile duct damage or hepatitis-associated bile 
duct damage and is often observed in chronic active hepatitis, including AIH and 
chronic viral hepatitis (in particular, HCV-related disease) (Fig. 15). These bile duct 
damages sometimes accompany destructive changes (up to 12% of biopsies) [1], and 
resemble chronic nonsuppurative destruction cholangitis (CNSDC) of PBC (Fig. 15). 
The observation of bile duct lesions alone cannot be used to differentiate AIH from PBC 
[22]. However, the bile duct loss found in biliary diseases such as PBC and PSC is 
rarely observed in AIH. 
 
4.5 Histological staging and grading system 
 Liver biopsy provides information regarding the staging of fibrosis and the degree 
of hepatic inflammation as well as the diagnosis of AIH. However, there is no scoring 
system that reflects the unique histological features of AIH. Regarding the staging and 
grading systems for AIH, four systems, such as those described by Batts and Ludwig 
[23] and Scheuer (Table 1) [24], the French Metavir system [25], and the modified 
histological activity index (Table 2) [26] for chronic viral hepatitis are diverted. In Japan, 
the New Inuyama Classification [27] is diverted as a grading and staging system that 
reflects activity and fibrosis, although this originally should be applied to chronic viral 
hepatitis. In this classification, the degree of necroinflammatory change (grading or 
activity system) is classified into the following four categories that take into 
consideration portal inflammation including interface hepatitis and parenchymal 
inflammation: A0 (minimal: no or minimal necroinflammatory change), A1 (mild: mild 
necroinflammatory change), A2 (moderate: moderate necroinflammatory change), and 
A3 (severe: marked necroinflammatory change including confluent necrosis, such as 
zonal and bridging necrosis). A staging score has been developed to reflect the extent of 
portal fibrosis. Fibrosis stages are as follows: F0 (no fibrosis: no or minimal portal 
fibrosis), F1 (mild fibrosis: as above, with portal fibrous enlargement), F2 (moderate 
fibrosis: as above, with bridging fibrosis), F3 (severe fibrosis: as above, with lobular 
disarray), and F4 (cirrhosis). 
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4.6 Liver cirrhosis 
Cirrhosis is the terminal stage of AIH. However, at the diagnosis of AIH, 6.4% 
of AIH cases in Japan have already progressed to cirrhosis [28]. Moreover, cirrhosis of 
AIH is a risk factor for hepatocellular carcinoma, although its incidence is lower than 
that observed in hepatitis virus-related cirrhosis [29]. In general, cirrhosis is thought to 
be an irreversible terminal stage, regardless of etiology. However, in cases that exhibit 
great clinical improvement after immunosuppressive treatment, fibrosis and cirrhosis 
regression, as well as hepatocellular regeneration, result in the disappearance of the 
remnant of cirrhosis. In contrast, AIH-related cirrhosis, although inactive, is thought to 
be caused by a burnt-out process without specific laboratory findings and absent disease 
activity. Therefore, as in the preceding diseases of cryptogenic cirrhosis, AIH and 
nonalcoholic steatohepatitis are usually at the top of the list. 
 
4.7 Variations of AIH 
4.7.1 Acute AIH 
Some AIH patients show a clinically acute hepatitis-like clinical course. These 
AIH patients have mostly acute exacerbation from chronic active AIH (Fig. 16) but 
acute-onset or fulminant AIH cases with diffuse and severe hepatocellular damage 
without definite chronicity, such as fibrosis and preceding liver dysfunction, have also 
been reported (Figs 17 and 18) [30]. These acute AIH cases have higher serum bilirubin, 
transaminase, and γ-GTP compared with ordinary chronic AIH. In contrast, the serum 
levels of IgG and γ-globulin and the titer of autoantibodies are not generally high. 
Therefore, it is difficult to diagnose acute AIH using the international criteria as 
mentioned above. Liver biopsy is useful for the diagnosis of acute AIH. There is portal 
inflammation and diffuse lobular necroinflammation (Fig. 17). Perivenular zonal 
necrosis and bridging necrosis among portal tracts and central veins, and rarely 
periportal zonal necrosis, may accompany lobular disarray (Figs 18 and 19) [31-33]. In 
some cases, zonal necrosis (zone 3 necrosis, centrozonal necrosis) located around the 
central vein, similar to a characteristic of drug-induced liver injury, is prominent 
(Fig.20) [34,35]. Zone 3 necrosis has not been formally included in the histological 
features of AIH but is thought to be a characteristic feature of acute-onset AIH. 
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4.7.2 PBC–AIH overlap syndrome 
AIH and PBC may simultaneously or metachronously coexist in some patients, 
which is designated as PBC–AIH overlap syndrome. Previous studies suggest that 
combination therapy of ursodeoxycholic acid (UDCA) and corticosteroids may be 
effective in these cases. Although its pathogenesis has been discussed for a long time, 
according to the statements of IAIHG, this overlap syndrome has been regarded as a 
subtype of PBC with the feature of AIH-like severe hepatitic change [36] and 
corresponds to the disease group that has been formerly called hepatitic PBC. Although 
AIH-like features are dominant in liver histology, distinct PBC features, such as 
CNSDC and bile duct loss, are also observed (Fig.21). 
Chazouilleres’s criteria [37] (Paris criteria) has been used as the diagnostic 
criteria for this overlap syndrome, and the simplified AIH system of the IAIHG has 
been used as the criteria for the AIH feature in PBC. Steroid therapy (PSL) is 
recommended in addition to UDCA for cases that are considered to be PBC–AIH 
overlap syndrome. The Intractable Hepatobiliary Disease Study Group in Japan (2011) 
recommends PSL in addition to UDCA for cases that are considered to be PBC–AIH 
overlap syndrome and simultaneously meet the two following criteria: (1) diagnosis of 
PBC using the criteria of the Intractable Hepatobiliary Disease Study Group in Japan 
(2010) and (2) diagnosis of probable/definite AIH using IAIHG simplified criteria 
(2008). Regarding liver histology, hepatitic activity (HA) scores in the PBC 
grading/staging system should be used as follows: 0 points for HA score 0 or 1, 1 point 
for HA score 2, and 2 points for HA score 3 [38,18,39]. Because the presence of 
emperipolesis, which is not familiar to clinicians and even pathologists, is not required 
to survey the disease, pathological evaluation becomes relative easy. 
 
4.8 Conclusion 
In the diagnosis and management of AIH, liver biopsy is an essential element, 
because individual histological, serological, and clinical features are not specific for the 
diagnosis of AIH. Histological examination of liver biopsies helps exclude other 
potential causes of liver disease and identify variant syndromes. Therefore, AIH is 
thought to be a clinicopathological entity, and the communication between pathologists 
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and clinicians is crucial in AIH. 
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Fig.1 Typical autoimmune hepatitis (AIH) showing chronic active hepatitis. 
Enlargement of portal tracts and bridging formation (A, arrow) are observed. 
In inflamed portal tracts, bile duct damage is observed (B, arrow). 
 
Fig.2 Typical autoimmune hepatitis (AIH) showing chronic active hepatitis. In 
enlarged portal tracts, severe inflammatory cells infiltration and follicle-like 
aggregation (*) are observed (A). Interface hepatitis is also prominent (arrows 
in A and B). Inflammatory cells consist of lymphocytes and plasma cells (B). 
B is a higher magnification of A. 
 
Fig.3 Parenchymal change in autoimmune hepatitis (AIH) showing chronic active 
hepatitis. In parenchyma, many focal necrosis are observed. This lobular 
hepatitis is prominent in AIH. 
 
Fig.4 Confluent necrosis. Bridging necrosis (A, arrow) and perivenular zonal 
necrosis (B) are observed in AIH cases. 
 
Fig.5 Ballooning degeneration of hepatocytes (*) is observed in the periportal area in 
autoimmune hepatitis (AIH). 
 
Fig.6 The present of acidophilic bodies indicating the apoptosis of hepatocytes 
(arrows) reflects the marked parenchymal hepatitis in autoimmune hepatitis 
(AIH). 
 
Fig.7 Hepatocyte rosette formation (arrow) around a severe interface hepatitis area. 
 
Fig.8 Pigmented macrophages (arrows) are scattered in a necrotic area of 
autoimmune hepatitis (AIH). 
 
Fig.9 Giant syncytial multinucleated hepatocytes (arrows) are present in some 
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autoimmune hepatitis (AIH) cases. 
 
Fig.10 Broad collapse of hepatocytes (arrows) in acute exacerbation of autoimmune 
hepatitis (AIH). 
 
Fig.11 Immunohistochemistry for T-bet (A) and Foxp3 (B). Many T-bet-positive 
Th1-type T cells are observed in portal tracts (PT) and parenchyma (P) (A). 
Foxp3-positive Treg cells are scattered in PTs (B). 
 
Fig.12 Biliary changes raised by modified criteria (1999) of the autoimmune hepatitis 
(AIH) scoring system. A: Granulomatous cholangitis in primary biliary 
cirrhosis. B: Severe concentric periductal fibrosis in primary sclerosing 
cholangitis. C: Ductopenia. The portal vein (P) and artery (A) are found, but 
the bile duct is missing. D: Orcein staining. Copper-binding proteins are 
scattered in hepatocytes. 
 
Fig.13 Immunological contact pattern between target cells and lymphocytes. 
Emperipolesis is a unique feature of penetration of lymphocytes into 
hepatocytes, and the tightest pattern of target cells (hepatocytes) and effector 
cells (lymphocytes). 
 
Fig.14 Emperipolesis in autoimmune hepatitis (AIH). Emperipolesis is observed 
around the interface area. Although arrows indicate emperipolesis, all arrows 
are possibly hard to evaluate as emperipolesis. 
 
Fig.15 Bile duct damage (hepatitic bile duct injury) in autoimmune hepatitis (AIH). 
Arrows denote the damaged interlobular bile ducts at various degrees. In 
particular, bile ducts in C and D show destructive changes resembling chronic 
nonsuppurative destructive cholangitis (CNSDC) of primary biliary cirrhosis 
(PBC). 
 
Fig.16 Acute exacerbation of autoimmune hepatitis (AIH). A: Many focal necroses are 
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diffusely seen in parenchyma. B: Bridging necrosis (arrow) is observed 
between enlarged portal tracts with inflammation (P). 
 
Fig.17 Acute-onset autoimmune hepatitis (AIH) case. In parenchyma, many focal 
necroses and pigmented macrophages are scattered and accumulate around 
the central vein (C). Portal tracts (P) are almost preserved. 
 
Fig.18 Acute-onset autoimmune hepatitis (AIH) case without preceding liver 
dysfunction. A: Lower magnification. A diffuse inflammatory change is 
observed. B: Perivenular zonal necrosis is observed (arrows). C: Bridging 
necrosis is seen between portal tracts. D: Although mild inflammation and 
edema are observed in portal tracts, reticulin staining shows no distinct 
fibrous enlargement. 
 
Fig.19 Acute-onset autoimmune hepatitis (AIH) case without preceding liver 
dysfunction and drug intake. Antinuclear antibody is positive (1280). In 
addition to diffuse lobular hepatitis, periportal zonal necrosis is observed 
(arrows, A). Azan–Mallory staining indicates and absence of fibrosis in the 
zonal area (arrows, B). 
 
Fig.20 Two cases of acute-onset autoimmune hepatitis (AIH) showing zone 3 necrosis. 
A and B: Perivenular zonal necrosis with hemorrhage is observed but portal 
inflammation is minimal (P). C and D: Perivenular zonal necrosis resembling 
hepatocellular necrosis of drug-induce liver injury is observed. 
 
Fig.21 Two cases of primary biliary cirrhosis–autoimmune hepatitis (PBC–AIH) 
overlap syndrome (hepatitic PBC). In addition to chronic nonsuppurative 
destruction cholangitis (CNSDC) (arrows), marked portal inflammation is 
observed. In the case on the right (B), interface hepatitis and lobular hepatitis 
(*) are also prominent. 
Scheuer classification for grading and staging of chronic hepatitis 
 
Grade   Portal/periportal activity   Lobular activity 
0  None     None 
1  Portal inflammation   Inflammation but no necrosis 
2  Mild piecemeal necrosis   Focal necrosis or acidophil bodies 
3  Moderate piecemeal necrosis  Severe focal cell damage 
4  Severe piecemeal necrosis   Damage includes bridging necrosis 
 
Stage Fibrosis 
0  None 
1  Enlarged, fibrotic portal tracts 
2  Periportal or portal-portal septa, but intact architecture 
3  Fibrosis with architectural distortion, but no obvious cirrhosis 
4  Probable or definite cirrhosis 
Table 1 
Ishak modified hepatic activity index (HAI) for scoring of necroinflammatory activity and staging in chronic hepatitis 
 
Necroinflammatory scores 
(A) Periportal or periseptal interface hepatitis (piecemeal necrosis) 
        Absent       0 
        Mild (focal, few portal areas)    1 
        Mild/moderate (focal, most portal areas)   2 
        Moderate (continuous around <50% of tracts or septa)  3 
        Severe (continuous around >50% of tracts or septa)    4 
(B) Confluent necrosis 
        Absent      0 
        Focal confluent necrosis     1 
        Zone 3 necrosis in some areas    2 
        Zone 3 necrosis in most areas    3 
        Zone 3 necrosis+occasional portal-central (P-C) bridging  4 
        Zone 3 necrosis + multiple P-C bridging    5 
        Panacinar or multiacinar necrosis    6 
(C) Focal (spotty) lytic necrosis, apoptosis and focal inflammation 
        Absent      0 
        One focus or less per x10 objective    1 
        Two to four foci per x10 objective    2 
        Five to ten foci per x10 objective    3 
        More than ten foci per x10 objective    4 
(D) Portal inflammation 
        Absent      0 
        Mild, some or all portal areas    1 
        Moderate, some or all portal areas    2 
        Moderate/marked, all portal areas    3 
        Marked, all portal areas     4 
 
Staging  
        No fibrosis    0 
        Portal fibrosis, with or without short fibrous septa  1 
        Fibrous septa    2 
        Transition to cirrhosis    3 
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